← Holders
Ishara Investments LP
What Ishara Investments LP reported holding on Form 13F for the quarter ended Sep 30, 2026.
CIK 2111609 · Filed Nov 16, 2026
- Positions
- 41
- Reported value
- $121M
- Opened
- 17
- Closed
- 17
- Other managers included
- 0
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
Quarters on file
- Dec 31, 2025$87.5M38 positions
- Mar 31, 2026$105.6M37 positions
- Jun 30, 2026$136.1M41 positions
- Sep 30, 2026$121M41 positions
| Security | Shares | Change | Value | Of portfolio |
|---|---|---|---|---|
TVTXTravere Therapeutics, Inc. | 145K | +76.8% | $8.5M | 7.1% |
CYTKCytokinetics Inc | 128K | +290.2% | $8.4M | 7% |
BBIOBridgeBio Pharma, Inc. | 100K | +74.2% | $6.6M | 5.4% |
ACADAcadia Pharmaceuticals Inc | 320K | −22.0% | $6.4M | 5.3% |
TARSTarsus Pharmaceuticals, Inc. | 70K | New | $5.5M | 4.5% |
PTCTPTC Therapeutics, Inc. | 80K | New | $5.2M | 4.3% |
PRAXPraxis Precision Medicines, Inc. | 17K | −24.6% | $5M | 4.1% |
VERAVera Therapeutics, Inc. | 150K | +1,363.4% | $4.8M | 4% |
ARQTArcutis Biotherapeutics, Inc. | 180K | New | $4.8M | 3.9% |
ANNXAnnexon, Inc. | 1.1M | +36.6% | $4.7M | 3.9% |
UTHRUnited Therapeutics Corp | 8K | New | $4.3M | 3.6% |
NAMSNewAmsterdam Pharma Co N.V. | 160K | +333.6% | $3.9M | 3.2% |
XERSXeris Biopharma Holdings, Inc. | 400K | −67.5% | $3.8M | 3.2% |
CELCCelcuity Inc. | 48K | New | $3.8M | 3.2% |
DBVTDBV Technologies S.A. | 270K | +46.3% | $3.2M | 2.6% |
VRDNViridian Therapeutics, Inc. | 150K | New | $3.1M | 2.6% |
ZNTLZentalis Pharmaceuticals, Inc. | 1.1M | +5.4% | $3M | 2.5% |
BMRNBioMarin Pharmaceutical Inc | 48K | −66.6% | $2.9M | 2.4% |
BIIBBiogen Inc. | 12K | New | $2.7M | 2.2% |
MLYSMineralys Therapeutics, Inc. | 100K | −2.4% | $2.5M | 2.1% |
LGNDLigand Pharmaceuticals Inc | 8K | New | $2.5M | 2.1% |
RAREUltragenyx Pharmaceutical Inc. | 160K | −22.0% | $2.4M | 2% |
PCVXVaxcyte, Inc. | 40K | −51.2% | $2.3M | 1.9% |
ORICOric Pharmaceuticals, Inc. | 160K | +30.1% | $2.2M | 1.8% |
AXSMAxsome Therapeutics, Inc. | 10K | −39.0% | $1.8M | 1.5% |
SLNSilence Therapeutics plc | 160K | +189.1% | $1.7M | 1.4% |
BEAMBeam Therapeutics Inc. | 70K | +70.7% | $1.7M | 1.4% |
BHVNBiohaven Ltd. | 120K | New | $1.6M | 1.3% |
| 1K | New | $1.5M | 1.2% | |
CTNMContineum Therapeutics, Inc. | 108K | −47.3% | $1.4M | 1.2% |
GMABGenmab A/S | 40K | −61.0% | $1.4M | 1.2% |
NBIXNeurocrine Biosciences Inc | 8K | New | $1.1M | 0.9% |
MNPRMonopar Therapeutics | 12K | −2.4% | $956K | 0.8% |
MLTXMoonLake Immunotherapeutics | 80K | New | $936K | 0.8% |
SPRYARS Pharmaceuticals, Inc. | 200K | +39.4% | $862K | 0.7% |
IONSIonis Pharmaceuticals Inc | 16K | New | $714.4K | 0.6% |
OLMAOlema Oncology, Inc. | 80K | New | $691.2K | 0.6% |
LXRXLexicon Pharmaceuticals, Inc. | 320K | −74.8% | $600K | 0.5% |
WVEWave Life Sciences, Inc. | 160K | New | $592K | 0.5% |
SVRASavara Inc | 80K | New | $412.8K | 0.3% |
GOSSGossamer Bio, Inc. | 24K | New | $284.4K | 0.2% |